JLE

Hépato-Gastro & Oncologie Digestive

MENU

Role of circulating tumor DNA in the management of patients with colorectal cancer Volume 25, issue 4, Avril 2018

  • [1] Taly V, Pekin D, Benhaim L, et al. Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients. Clin Chem 2013 ; 59 (12) : 1722-31.
  • [2] Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014 ; 20 (4) : 430-5.
  • [3] Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012 ; 486 (7404) : 532-6.
  • [4] Diehl F., Li M., Dressman D. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102:16368-16373. 45
  • [5] Taly V., Pekin D., Abed A.E., Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med. 2012;18:405-416. 7
  • [6] Laurent-Puig P, Pekin D, Normand C, et al. Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy. Clin Cancer Res 2015 ; 21 (5) : 1087-97.
  • [7] Pécuchet N., Rozenholc Y., Zonta E. Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. Clin Chem. 2016;62:1492-1503. 11
  • [8] Van Cutsem E., Cervantes A., Adam R. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-1422. 8
  • [9] Spindler K-LG, Pallisgaard N., Vogelius I., Jakobsen A. Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. Clin Cancer Res. 2012;18:1177-1185. 4
  • [10] Bachet JB, Bouché O, Taieb J, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy061.
  • [11] Spindler K-LG, Pallisgaard N., Appelt A.L. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. Eur J Cancer. 2015;51:2678-2685. 17
  • [12] Bettegowda C., Sausen M., Leary R.J. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014;6:224ra24-1224ra. 224
  • [13] Thierry A.R., El Messaoudi S., Mollevi C. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017;28:2149-2159. 9
  • [14] Diehl F., Schmidt K., Choti M.A. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-990. 9
  • [15] Ryan B.M., Lefort F., McManus R. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: Strong prognostic indicator in postoperative follow up. Gut. 2003;52:101-108. 1
  • [16] Tie J., Wang Y., Tomasetti C. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92-1346ra. 346
  • [17] Tie L, et al. Meeting Library | The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). [Internet]. [cited 2017 Oct 19]. Available from : https ://meetinglibrary.asco.org/record/147447/abstract.
  • [18] Overman MJ, et al. Meeting Library | Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. [Internet]. [cited 2017 Oct 19]. Available from : https ://meetinglibrary.asco.org/record/147351/abstract.
  • [19] Tie J., Kinde I., Wang Y. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26:1715-1722. 8
  • [20] Garlan F, Laurent-Puig P, Sefrioui D, et al. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clin Cancer Res 2017 ; 23 (18) : 5416-25.
  • [21] Diaz Jr LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012 ; 486 (7404) : 537-40.
  • [22] Spindler K-LG, Pallisgaard N., Andersen R.F., Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer--Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014;135:2215-2222. 9
  • [23] Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015 ; 21 (7) : 795-801.
  • [24] Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 2012 ; 23 (9) : 2313-8.
  • [25] Bardelli A., Corso S., Bertotti A. Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discov. 2013;3:658-673. 6